Compare Expeditors International of Wshngtn Inc (EXPD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Expeditors International of Wshngtn Inc trades at $197.41 (market cap $25.53B), while Spyre Therapeutics Inc. Common Stock trades at $80.16 (market cap $7.35B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and Expeditors International of Wshngtn Inc pays a 0.82% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EXPD | SYRE | |
|---|---|---|
Market Cap | $25.53B | $7.35B |
Volume | 1,068,336 | 1,624,631 |
Sector | Industrials | Health |
52-Week High | $196.38 | $108.92 |
52-Week Low | $117.35 | $22.18 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $25.06B | $6.35B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $195.13, up 0.89% with a bullish technical signal supported by moving averages. The company shows strong profitability with 7.63% net margin and 42.6% ROE, though revenue growth has been modest. Recent earnings beats and positive analyst coverage highlight operational efficiency, while institutional activity shows mixed positioning.
Outlook remains cautiously optimistic with upside to the $220 high target, but valuation multiples appear stretched. Key risks include freight market volatility and competitive pressures. The stock's current price above consensus target suggests limited near-term upside despite strong fundamentals.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
